RBOT - Vicarious Surgical Inc.
NYSE
->
Healthcare
->
Medical Devices
Waltham,
United States
Type: Equity
RBOT price evolution
RBOT
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $63.98 | $75.93 | $87.11 | $100.95 |
| Long term investments | ||||
| Property, plant & equipment | $15.61 | $16.35 | $17.13 | $17.86 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $80.62 | $93.35 | $105.29 | $119.86 |
| Current liabilities | ||||
| Accounts payable | $2.42 | $1.35 | $1.27 | $1.26 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $8.6 | $7.18 | $5.08 | $7.28 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $22.73 | $21.49 | $21.28 | $21.89 |
| Shareholders' equity | ||||
| Retained earnings | -$182.01 | -$164.92 | -$149.71 | -$132.71 |
| Other shareholder equity | $0.12 | -$0.05 | -$0.04 | $0.01 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1.1 | |||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $100.95 | $120.4 | $178.37 | $1.23 |
| Long term investments | ||||
| Property, plant & equipment | $17.86 | $18.86 | $2.25 | $0.45 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $345.19 | |||
| Total investments | ||||
| Total assets | $119.86 | $140.29 | $181.68 | $346.42 |
| Current liabilities | ||||
| Accounts payable | $1.26 | $1.73 | $1.5 | $0.01 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $7.28 | $8.39 | $6.25 | $0.13 |
| Long term debt | $0.69 | $0.06 | ||
| Total noncurrent liabilities | $341.3 | |||
| Total debt | ||||
| Total liabilities | $21.89 | $29.25 | $98.59 | $341.42 |
| Shareholders' equity | ||||
| Retained earnings | -$132.71 | -$61.64 | -$66.8 | -$9.46 |
| Other shareholder equity | $0.01 | |||
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $17.75 | $17.71 | $16.11 | $15.54 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $0.8 | $0.92 | $0.97 | $0.94 |
| Net income | ||||
| Net income | -$17.09 | -$15.21 | -$17 | -$13.11 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $80.67 | $80.08 | $38.21 | $0.35 |
| Operating income | -$0.35 | |||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $4.4 | $1.24 | -$0.07 | |
| Net income | ||||
| Net income | -$71.07 | $5.16 | -$35.21 | -$9.46 |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$7.59 | -$7.09 | -$0.14 | -$45.78 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $0 | $0 | $0 | $44.7 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$45.75 | -$32.57 | -$14.6 | -$63.39 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Net income | -$9.46 | |||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$0.43 | |||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$45.78 | -$5.35 | -$1.29 | -$345 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $44.7 | $9.15 | $192.16 | $346.52 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$63.39 | -$57.41 | $157.57 | $1.1 |
News
Fundamentals
| Market cap | $34.56M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 5.91M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$62.41M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -0.55 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$10.56 |
|---|---|
| ROA | -62.55% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 7.44 |
| Quick ratio | N/A |